Skip to main content
. 2022 Jan 26;12:38. doi: 10.1038/s41398-022-01811-6

Table 1.

Demographics and clinical data.

SCZ, N = 595 BD, N = 409 HC, N = 947 SMD vs HCa Subgroup comparisonsb
Sex female, N (%) 253 (42.5) 240 (58.7) 436 (46.0) ns HC, BD > SCZ
Age, mean (SD) 31.6 (10.1) 35.0 (12.4) 34.0 (9.3) 0.04 HC, BD > SCZ
GAF-symptoms, mean (SD) 45 (12) 58 (12) n/a BD > SCZ
GAF-function, mean (SD) 46 (13) 56 (13) n/a BD > SCZ
Medication, N (%)
 Antipsychotics 494 (83.0) 200 (48.9) n/a SCZ > BD
 Anticonvulsants 82 (13.8) 147 (35.9) n/a BD > SCZ
 Lithium 15 (2.5) 69 (16.9) n/a BD > SCZ
 Antidepressants 170 (28.6) 147 (35.9) n/a BD > SCZ
Diagnose, N (%)
 Schizophrenia 339 (57.0) n/a n/a
 Schizophreniform 36 (6.1) n/a n/a
 Schizoaffective 85 (14.3) n/a n/a
 Bipolar disorder 1 229 (56.0) n/a n/a
 Bipolar disorder 2 123 (30.1) n/a n/a
 Bipolar disorder NOS 19 (4.6) n/a n/a
 Major depressive disorder 38 (9.3) n/a n/a
 Psychosis NOS 82 (13.8) n/a n/a
 Brief psychotic disorder 14 (2.4) n/a n/a
 Delusional disorder 39 (6.6) n/a n/a

BD bipolar spectrum disorders, GAF general assessment of functioning scale, ns not significant, n/a not applicable, SCZ schizophrenia spectrum disorders, SMD severe mental disorders.

aP value of SMD versus HC: chi square for categorical variables, t test for continuous variables, bchi square for categorical variables, ANOVA for continuous variables.